文献速递乳房整形与再造创面修复

经微生物学证实的乳房假体与组织扩张器感染:复发危险因素与最优治疗策略评估

Microbiologically confirmed tissue expander and breast implant infections: Evaluating risk factors for recurrence and optimal treatment strategies.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-05-30

单中心回顾性队列纳入67例假体感染和107例组织扩张器感染,比较一期置换、二期置换和取出三种策略。假体感染复发率16%、扩张器21%,一期置换复发最高(38%和60%),二期置换与取出复发率较低;扩张器病例中抗生素间隔物使用与复发风险独立相关(校正OR 5.38,95%CI 1.06-27.22)。

要点

  • 一期置换复发率最高,假体38%、扩张器60%。
  • 二期置换与取出复发率较低,可考虑用于合适患者。
  • 扩张器感染中使用抗生素间隔物与复发风险升高独立相关。

核心结论

  • 二期置换和取出与较低的感染复发相关,在选定患者中可能是有利策略。
  • 条件允许时应考虑延迟再造。
  • 间隔物使用与复发的关联需进一步研究。

研究设计与样本

  • 单中心回顾性队列研究,纳入2017至2024年经微生物学证实的假体或组织扩张器感染成年女性。
  • 共纳入67例假体感染和107例组织扩张器感染。
  • 主要结局为干预后12个月内感染复发,次要结局包括血肿、血清肿、包膜挛缩和坏死。
  • 采用logistic回归和生存分析比较一期置换、二期置换和取出三种策略。

主要发现

  • 假体感染复发率为16%,组织扩张器感染复发率为21%。
  • 一期置换复发率最高:假体38%,组织扩张器60%。
  • 二期置换和取出与较低复发率相关;多变量模型中这些策略与复发风险降低相关,但部分比较未达统计学显著性。
  • Kaplan-Meier分析显示一期置换的无复发生存较差。
  • 组织扩张器病例中,抗生素间隔物使用与复发风险升高独立相关(校正OR 5.38,95%CI 1.06-27.22)。

临床怎么用

  • 对经微生物学证实的假体或扩张器感染,二期置换或取出可能优于一期置换。
  • 条件允许时考虑延迟再造以降低复发风险。
  • 扩张器感染使用抗生素间隔物时需警惕复发风险升高。

局限性

  • 单中心回顾性设计。
  • 部分策略比较未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2024, approximately 760,000 breast reconstructions were performed in the United States, including over 160,000 post-mastectomy procedures. Breast prosthesis infections, reported in 1-35% of cases, compromise esthetic outcomes, delay adjuvant therapy, and increase morbidity and recurrence risk. Data on predictors of recurrence and the impact of surgical strategies remain limited. METHODS: We conducted a single-center retrospective cohort study of adult women with microbiologically confirmed implant or tissue expander infections (2017-2024). The primary outcome was infection recurrence within 12 months of intervention. Secondary outcomes included post-operative complications (hematoma, seroma, capsular contracture, necrosis). Outcomes were compared across three surgical strategies - one-stage exchange, two-stage exchange, and explantation - using logistic regression and time-to-event analyses to assess recurrence-free survival. RESULTS: 67 implant and 107 tissue expander infections were included. Recurrence occurred in 16% of implant and 21% of tissue expander cases. One-stage exchange had the highest recurrence (38% implant, 60% tissue expander), while two-stage exchange and explantation were associated with lower recurrence rates. In multivariable models, these strategies were associated with reduced recurrence risk, although some comparisons did not reach statistical significance. Kaplan-Meier analysis demonstrated inferior recurrence-free survival with one-stage exchange. Among tissue expander cases, antibiotic spacer use was independently associated with increased recurrence risk (adjusted OR 5.38, 95% CI 1.06-27.22). CONCLUSION: Two-stage exchange and explantation were associated with lower infection recurrence and may represent favorable strategies in selected patients. Delayed reconstruction should be considered when feasible. The association between spacer use and recurrence warrants further investigation.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Igwilo-Alaneme R, Ranganath N, Vijayasekaran A, et al. Microbiologically confirmed tissue expander and breast implant infections: Evaluating risk factors for recurrence and optimal treatment strategies. J Plast Reconstr Aesthet Surg. 2026. PMID: 42330599. doi:10.1016/j.bjps.2026.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。